Business Wire

CA-CYGNVS-INC.

24.1.2023 14:01:50 CET | Business Wire | Press release

Share
CYGNVS™ Launches First-Ever Guided Platform for Cyber Crisis Preparedness and Response Management

CYGNVS Inc. today emerged from stealth backed by $55 million in series A funding and unveiled its pioneering guided cyber crisis platform purpose-built to empower organizations to stay Connected, Confident, in Control and Compliant as they prepare for and respond to any cyber crisis.

“No matter how much is spent on cybersecurity, cyber crises are inevitable and every organization in the world needs to prepare and plan for that eventuality,” said Marc Goodman, global security advisor and The New York Times bestselling author of “Future Crimes.” “Successful response is surprisingly complex, and most victims fail because they try to cobble together their response at that time. Being prepared and having a practiced plan is critical to any organization’s cyber resilience."

When a cyber crisis does occur, preparation and practice can make a big difference. From data in The Cost of Data Breach Report 2022, organizations that are better prepared and practiced save an average of $1.38 million in direct costs.

CYGNVS (an acronym of CYber GuidaNce Virtual Space) empowers organizations to reduce their risk before a cyber crisis through preparation and practice and then reduce cost and impact of a cyber crisis with a guided, accelerated response.

Partnering With Insurance

Just as the insurance industry helped drive adoption of building sprinkler systems, which greatly reduced fire risk, the cyber insurance industry has deep expertise in cyber crisis preparation and response.

CYGNVS has partnered with AIG, a leading worldwide provider of cyber insurance. After responding to thousands of cyber breaches, AIG identified various critical challenges to optimize breach response, such as a client’s visibility into the entire end-to-end response process, secure post-event communications, and working effectively and consistently with external response providers including breach counsel and forensic consultants. AIG helped CYGNVS develop the requirements by providing guidance based on AIG’s experience, expertise and thought leadership in cyber claim resolutions, enabling CYGNVS to develop a robust platform to address the problems of organizations worldwide.

Today, CYGNVS insurance customers together represent half the cyber insurance market and CYGNVS is being rolled out to clients by leading insurers and brokers complementing their cyber insurance policies.

Back To Business, Faster

With CYGNVS, organizations can quickly assemble everyone contributing to the cyber crisis response in a safe, secure environment out of bank from internal channels. The platform converts static breach response plans into interactive and actionable processes and checklists. Internal teams and outside experts can be assigned roles and responsibilities, tasks are communicated in a digestible fashion and plans and workstreams can be easily and quickly updated as people, assets, regulations and threats change.

“CYGNVS was founded with the mission of making the world’s organizations lower their cyber risk by addressing the critical areas of preparation and response. We purpose-built CYGNVS as a guided cyber crisis platform to empower organizations to be Connected, Confident, in Control and Compliant before, during, and after a cyber crisis,” said Arvind Parthasarathi, Founder and CEO of CYGNVS.

CONNECTED

  • Out-of-band, Secure, Mobile
  • Accessible Anytime, Anywhere – mobile apps for iOS/Android and all browsers
  • Pre-setup, Pre-configured and Ready-to-go
  • Rapidly assemble team, assign roles, and initiate response

CONFIDENT

  • Pre-built playbooks and Industry Templates
  • Rapidly plug in ecosystem of already onboarded external experts like lawyers, forensics, insurance
  • Practice and Simulate to build muscle memory
  • Guided workflow supports new or inexperienced team members

CONTROL

  • Guided, step-by-step, response execution
  • Single Unified Command Center
  • Visibility, Tracking, Alerts across Workstreams
  • Ensure all required steps are performed with no missteps

COMPLIANT

  • Fine grained access control across internal and external teams
  • Help maintain privilege by managing information access
  • Audit trail of documented evidence
  • Simplify reporting to Regulators, Customers, and other stakeholders

CYGNVS is SOC2 Type 2 certified and ISO 27001 compliant and has been built from the ground up with industry-leading security standards, including multi-factor authentication (MFA), encrypting all data in transit and at rest, and separation and isolation best practices.

$55 million Series A Funding Round

Led by Andreessen Horowitz, with participation from Stone Point Ventures and EOS Venture Partners, CYGNVS will use the series A funding to further enhance the platform while expanding sales operations.

"Traditional multi-tenant cloud architectures don't work for the complex access and security challenges in a cyber crisis preparation and response," said Angela Strange, General Partner, Andreessen Horowitz. "The experienced cloud and security team at CYGNVS has built a robust end-to-end cyber crisis operating system from the ground up for successful crisis preparation and response."

Available Today

CYGNVS is now generally available across all segments and offered in English, French, Spanish, German, and Japanese. CYGNVS can be purchased direct or accessed as a no-cost benefit of cyber insurance policies from leading insurers and brokers. To learn more or schedule a demo, visit www.CYGNVS.com.

About CYGNVS Inc.

CYGNVS is a guided cyber crisis response platform purpose-built to empower organizations to be Connected, Confident, in Control and Compliant before, during and after a cyber crisis. Backed by a $55 million series A round from Andreessen Horowitz, Stone Point Ventures, and EOS Venture Partners, CYGNVS is headquartered in Silicon Valley, with offices in Canada, India, and Ireland. ​For more information, visit www.CYGNVS.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005299/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye